Interventions
Participants were randomized to treatment with either acetazolamide capsules (125 mg) or identically looking placebo capsules, one in the morning and two in the evening with a total daily acetazolamide dose of 375 mg. Baseline measurements including assessment of visuomotor performance were performed at 760 m before starting the treatment. A few weeks after initial testing, participants were invited back to start treatment one day before ascent. They then travelled 3–5 hours by minibus to the high altitude clinic at 3,100 m, where they stayed for 48 hours.